Tisotumab vedotin, also named Humax®-TF, is an antibody-drug conjugate based on MMAE linked, via cathepsin cleavable linker, to a monoclonal antibody targeting tissue factor (TF), a transmembrane receptor and cofactor for factor VII/FVIIa [33], expressed by fibroblasts and epithelial cells and overexpressed in many tumors [98], including ovarian tumors [99]. The gene discussed is TF; the disease is ovarian neoplasm.